<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00946829</url>
  </required_header>
  <id_info>
    <org_study_id>502.425</org_study_id>
    <nct_id>NCT00946829</nct_id>
  </id_info>
  <brief_title>Study of Hypertensive Population Under Treatment With Telmisartan in Real Clinical Conditions With the Goal to Control Early Morning Blood Pressure Rise</brief_title>
  <official_title>Study of Hypertensive Population Under Treatment With Micardis in Real Clinical Conditions With the Goal to Control the Early Morning BP Rise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of the observational study is to ascertain the degree of blood pressure control in
      the early-morning hours after 8 weeks of treatment with
      Telmisartan/Telmisartan+Hydrochlorothiazide and during 44 weeks of follow-up, in patients
      with hypertension using home blood pressure measurements.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean early morning systolic blood pressure, mean early morning diastolic blood pressure, and degree of control. (6:00 to 11:59), BP &lt; 135/85 mmHg. (HBPM: mean of morning measurements).</measure>
    <time_frame>217 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical control (office BP), response rates, reduction in office cuff systolic and diastolic BP. Office BP control criteria: BP &lt; 140/90 mmHg. Pulse rate, pulse pressure, discontinuations and tolerability.</measure>
    <time_frame>217 Weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">18299</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary Care Clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with mild to moderate essential hypertension and whose medical condition make
             them eligible for treatment with Telmisartan/Telmisartan+HCTZ

        Exclusion Criteria:

          -  Pre-menopausal women who had had no birth control, who are pregnant or nursing

          -  Patients with advanced hepatic impairment, advanced renal impairment or both

          -  Patients with functional class III or IV (NYHA) congestive heart failure (CHF),
             unstable angina, acute myocardial infarction, heart surgery or stroke within the
             previous six months

          -  Patients with any valvular disease with hemodynamic repercussion

          -  Patients receiving chronic administration of oral anticoagulants or digoxin

          -  Patients with known hypersensitivity to any component in the formulation of Micardis /
             MicardisPlus

          -  Patients with previous history of angioedema associated with ACE inhibitors

          -  Patients with severe, uncontrolled hypertension or any form of secondary hypertension

          -  Patients with any other clinical conditions which, in the opinion of the investigator,
             would not allow for the safe completion of the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boehringer Ingelheim Investigational Site</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boehringer Ingelheim Investigational Site</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boehringer Ingelheim Investigational Site</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boehringer Ingelheim Investigational Site</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boehringer Ingelheim Investigational Site</city>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boehringer Ingelheim Investigational Site</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boehringer Ingelheim Investigational Site</city>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boehringer Ingelheim Investigational Site</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boehringer Ingelheim Investigational Site</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boehringer Ingelheim Investigational Site</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boehringer Ingelheim Investigational Site</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boehringer Ingelheim Investigational Site</city>
        <country>Yemen</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Ecuador</country>
    <country>Indonesia</country>
    <country>Jordan</country>
    <country>Lebanon</country>
    <country>Mexico</country>
    <country>Turkey</country>
    <country>Venezuela</country>
    <country>Yemen</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2009</study_first_submitted>
  <study_first_submitted_qc>July 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2009</study_first_posted>
  <last_update_submitted>July 24, 2009</last_update_submitted>
  <last_update_submitted_qc>July 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

